8th Annual USC Multidisciplinary Breast Cancer Symposium

 

Videos
05:35

8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+HER2- High-Risk eBC: Surveying Efficacy Data of CDK4/6i in the Adjuvant Setting

FEATURING George Sledge
  • 186 views
  • February 22, 2021
09:19

8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+/HER2- MBC: Outcomes of 1/2L CDK4/6 Inhibition

FEATURING George Sledge
  • 266 views
  • February 9, 2021
09:50

8th Annual USC Multidisciplinary Breast Cancer Symposium

ER+ Early Stage BC: Which Patients Should Avoid Chemotherapy? Does Chemo Add Benefit for Postmenopausal Women?

FEATURING George Sledge
  • 204 views
  • February 9, 2021
  • 1
06:22

8th Annual USC Multidisciplinary Breast Cancer Symposium

PI3K/AKT/mTOR Inhibition in Advanced BC: Is There Any Benefit With Alpelisib, Capivasertib, and Everolimus?

FEATURING George Sledge
  • 62 views
  • February 9, 2021
30:59

8th Annual USC Multidisciplinary Breast Cancer Symposium

Genetic Risk in BC: BRCA1/2 Mutations, Genetic Testing, Preventive Bilateral Mastectomy/Salpingo-Oophorectomy, Chemoprevention, NGS, Hereditary Syndromes

FEATURING Banu Arun
  • 17 views
  • February 9, 2021
35:08

8th Annual USC Multidisciplinary Breast Cancer Symposium

Oncoplastic Surgery and BC: What Is Extreme Oncoplasty? When Can We Use It?

FEATURING Melvin Silverstein
  • 41 views
  • February 9, 2021
  • 1
28:38

8th Annual USC Multidisciplinary Breast Cancer Symposium

Diagnostic MRI for Newly Diagnosed BC: Factors of Occult Lesions Detection, Predicting of pCR After Neoadjuvant Chemo, RFS After Neoadjuvant Chemo

FEATURING Stephen Sener
  • 474 views
  • February 9, 2021
  • 1
39:07

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Challenges in HER2+ BC Testing: IHC Guidelines, Biomarker Testing for Targeted Therapy Selection, FISH Gene Assessment/Testing

FEATURING Michael Press
  • 52 views
  • February 9, 2021
18:27

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: What Does the New Data on T-DXd Suggest? Do Neratinib-Based Regimens Improve Outcomes in CNS Metastases? Is There a Clinical Benefit of Retreating Pts With Pertuzumab?

FEATURING William Gradishar
  • 426 views
  • February 5, 2021
  • 2
11:34

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: Tucatinib Combo and HRQoL in Brain Mets, Margetuximab+Chemo vs. Tras+Chemo, Subcutaneous Formulations

FEATURING William Gradishar
  • 112 views
  • February 5, 2021
  • 1
19:06

8th Annual USC Multidisciplinary Breast Cancer Symposium

USC Update on 1L Chemo Combination for Advanced TNBC: Does the Addition of Atezolizumab or Pembrolizumab Make a Difference?

FEATURING Sara A. Hurvitz
  • 138 views
  • January 28, 2021
06:31

8th Annual USC Multidisciplinary Breast Cancer Symposium

Innovations in Management of mTNBC: PARP Inhibitors

FEATURING Sara A. Hurvitz
  • 358 views
  • January 28, 2021
  • 3
13:11

8th Annual USC Multidisciplinary Breast Cancer Symposium

Clinical Trial Data on ADCs in TNBC: Sacituzumab Govitecan Efficacy & Biomarkers Analysis, T-DXd, Ladiratuzumab Vedotin

FEATURING Sara A. Hurvitz
  • 241 views
  • January 28, 2021
  • 2